CivicaScript, a nonprofit generic drug company, has launched insulin glargine-yfgn and ustekinumab-aauz, expanding its national portfolio of low-cost treatments. The insulin product, which is ...
The logo of Sanofi is pictured during the Viva Tech start-up and technology summit in Paris, France, May 25, 2018. REUTERS/Charles Platiau/Files (Reuters) - U.S. generics drugmaker Mylan said on ...
New York, United States , June 12, 2024 (GLOBE NEWSWIRE) -- The Global Insulin Glargine Market Size is to Grow from USD 1.38 Billion in 2023 to USD 2.50 Billion by 2033, at a Compound Annual Growth ...
Stacker on MSNOpinion
Popular insulin medications and how they are used
SaveHealth reports that insulin therapy is crucial for diabetes management, with various options available, including rapid- ...
NEW ORLEANS--Merck & Co. won’t be the first to roll out a biosimilar version of Sanofi’s multibillion-dollar basal insulin, Lantus. But it aims to step up the competition when it does--and new data ...
Sanofi’s Lantus, its most commonly prescribed insulin, will sell for $35 a month through GoodRx Holdings Inc. in a deal that signals the drug-discount site’s growing business with large pharma ...
Civica plans to distribute its insulin glargine to pharmacies across the United States for $45 for a box of five pens. “Through the partnership we formed with Civica more than six years ago, BCBSA and ...
California is the first state in the country to partner with a nonprofit to develop, produce and sell its own insulin.
CivicaScript®, LLC, a nonprofit company dedicated to bringing low-cost generic medicines and biosimilars to U.S. patients, today announced the availability of two new products: insulin glargine-yfgn ...
FDA is aware of four recently-published observational studies that looked at the use of Lantus (insulin glargine) and possible risk for cancer in patients with diabetes. Three of the four studies ...
Merck announced that two Phase 3 studies evaluating MK-1293, an investigational, follow-on biologic insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes, achieved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback